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ABSTRACT : 
 
BACKGROUND: Antipsychotics produce EEG modifications and increase the risk of epileptic 
seizure. These modifications remain sparsely studied specifically for atypical antipsychotics. In this 
context, our study focuses on EEG modifications associated with atypical strict antipsychotic 
monotherapies. 
 
METHODS: EEG recordings of 84 psychiatric patients treated with atypical antipsychotics in strict 
monotherapy (clozapine: n=22, aripiprazole: n=22, olanzapine: n=17, risperidone: n=9, quetiapine: 
n=8, risperidone long-acting injection: n=4, and paliperidone long-acting injection: n=2) were 
analyzed. The modifications were ranked according to both slowing and excitability scores. 
 
RESULTS: EEG modifications (in 51 subjects, 60.71%) were graded according to 4 stages combining 
general slowing and sharp slow waves and/or epileptiform activities. The presence of sharp or 
epileptiform activities was significantly greater for clozapine (90,9%) compared to other second-
generation antipsychotics (aripiprazole: 50%, olanzapine: 58,8%, quetiapine: 37,5%, risperidone: 
44,4%). Age, duration of disease progression and diagnosis were not associated as risk factors. EEG 
modifications were associated with lower doses for treatment with quetiapine but not for specific 
antipsychotics. EEG modifications and severe excitability were associated with higher chlorpromazine 
equivalent doses. 
 
CONCLUSIONS: Atypical antipsychotics (clozapine, aripiprazole, quetiapine, olanzapine, 
risperidone) induce EEG modifications and these are significantly greater for clozapine and appear 
dependent on chlorpromazine equivalent dose. No encephalopathy was observed in these antipsychotic 
monotherapies, whatever dose. 
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 The effects of psychotropic substances on electroencephalogram (EEG) were reported 
shortly after its discovery in 19291. Hans Berger described in 1933 the EEG changes induced by 
barbiturates, morphine and scopolamine2. The first studies reporting anomalies induced by 
antipsychotics appeared at the end of the 1960s with studies on phenotiazine3–5. Dasberg and Robinson 
distinguished modifications associated with the toxic effects of drugs and abnormalities secondary to 
preexisting cerebral abnormalities5. Phenothiazine-type antipsychotics induce a slight slowing, 
amplitude increase, synchronization and anterior spreading of the alpha-activity6. Dasberg explains 
that the effects on the EEG of antipsychotics indicate changes in the cerebral environment that lead to 
a reorganization of behavior7. 
EEG modifications are common in patients with psychiatric disorders8. These modifications 
are also reported in approximately 20-40% of patients with mood disorders and 20-60% of patients 
with schizophrenia8. A high percentage of patients with schizophrenia display EEG modifications with 
generalized slow activity, dysrhythmia, spikes and spike-wave complexes9. Nevertheless, in their 
retrospective review of EEG request, O’Sullivan et al. assume that the majority of EEG modifications 
from psychiatric sources can be explained by psychotropic medications10. In these conditions, the EEG 
cannot be used for diagnosis of the mental diseases. However EEG can aid in determining whether 
patients suffering from mental disorders are taking the drugs prescribed, or whether the dosages 
administered is producing central nervous system side effects or toxicity11. 
Treatment with antipsychotics induces EEG modifications12. Mainly, a general slowing of the 
background activity, an increase in paroxysmal theta or delta activity and development of epileptiform 
discharges have been frequently reported in the literature13. Despite the introduction of various new 
molecules into the last thirty years, few studies have focused on EEG modifications induced by one or 
more atypical antipsychotics except for clozapine with its seizure risk12. However, paroxysmal EEG 
activity or slowing EEG was also suggested in addition of the therapeutical effect of other 
antipsychotics5,14. Some authors have suggested that EEG modifications related to clozapine are 
associated with a good therapeutic response15–17.  
Most authors use the term “abnormalities” to qualify these EEG modifications18. In medicine, 
the term "normal" is used to discern healthy from ill19. If EEG modifications are associated with the 
therapeutic effect, the term « EEG abnormalities » appears to be inappropriate in this case, because the 
word « abnormalities » suggests a deleterious effect18. Several authors support this concept18,20. Our 
study is descriptive and for this reason, we will use the descriptive term of « EEG modifications » and 
not « EEG abnormalities ». Indeed the design of our study was not developed to determine if the EEG 
modifications described is related to a side effect. 
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 Centorrino et al. demonstrated that EEG modifications appeared to be more severe with 
second-generation than with first-generation antipsychotics with a particularly high risk of 
modifications with clozapine (47.1%) and olanzapine (38.5%), a moderate risk for typical 
antipsychotics (14.5%) and risperidone (28%). In their study, severe modifications (spike discharges 
or spike-and-wave activity) was observed for clozapine (5.9%) and olanzapine (7.7%) and risperidone 
(4.0%), but not for haloperidol21. The risk factors facilitating significant EEG modifications were the 
presence of hypertension, the use of an atypical antipsychotic, the diagnosis of bipolarity and older 
age. Benzodiazepine co-treatment was considered as protective factor21. 
A study by Pillmann et al. about EEG analysis of 43 olanzapine-treated patients, showed an 
increase of diffuse slowdown (48.8%), intermittent slowing (34.9%) and epileptiform activity in some 
patients (9,3%)22. Another study on 54 patients treated with olanzapine demonstrated a significant EEG 
slowing, sharp waves and paroxysmal slow wave bursts respectively in 70,4%, 22,2% and 14,8% of 
treated patients. Co-treatment with another antipsychotic would increase EEG modifications while co-
treatment with benzodiazepines would decrease modifications23. 
Another study evaluated EEG in 81 patients receiving monotherapy with quetiapine, 
olanzapine, and haloperidol. One patient in the quetiapine group (5%), 13 patients receiving olanzapine 
(35%), 5 patients treated with haloperidol (22,8%) presented EEG modifications. Epileptiform 
activities was observed only in four patients (10,8%) of the olanzapine group13.  
In summary, the prevalence of EEG modifications appears to differ according to antipsychotic 
type. Prevalence of EEG modifications in people taking clozapine varies from 25% to 53% according 
to studies24. Quetiapine appears to induce less EEG modifications13,21,25. However, the number of EEG 
studies of atypical antipsychotics is reduced. 
In this context,  we conducted a comprehensive retrospective analysis of EEG recordings on 
patients with mental disorders and treated with atypical antipsychotic agents in strict monotherapy. 
We assumed that modifications might depend on the dose and type of antipsychotic. We considered 
combinations of EEG results with selected clinical and treatment factors. We hypothesized that severe 
EEG modifications would be associated primarily with clozapine and with a dose-dependent effect. 
 
METHODS: 
 
A data bank of 5217 EEG medical reports recorded from psychiatric patients admitted to the 
Sainte-Marguerite Psychiatric Hospital in Marseille between January 2012 and December 2016 was 
used. In this hospital, EEGs were systematically performed for initial assessment or when clinical signs 
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suggested another pathology or poor treatment tolerance.  
From this data bank, we extracted EEG of patients with a strict antipsychotic monotherapy 
(without any associated psychotropic molecule, including anticonvulsant, lithium, benzodiazepines or 
antidepressant). The exclusion criteria were age <18 years, epilepsy, brain tumor, stroke, traumatic 
brain injury without complete clinical recovery, multiple sclerosis, positive HIV test, previous drug 
overdose leading to coma, presence of known previous EEG abnormalities, treatment with 
electroconvulsive-therapy (ECT) in the previous 4 months of the EEG recording. 
The data collected in the medical records included sex, age, medical history, presence of 
psychiatric or neurological comorbidities, duration of disease, type of antipsychotic and daily dose 
administration prior to EEG registration. Long-acting antipsychotic injection doses were converted to 
an oral dose according to their oral dose equivalents. The doses of antipsychotic drugs (mg/day) were 
converted to chlorpromazine equivalents (mg/day) according to the equivalences established by 
Woods and al.26. 
Atypical antipsychotic agents were also divided into oral immediate-acting drugs (92.86% [n= 
78]) and long-acting injection drugs (7.14% [n=6]). Seven treatment groups were formed with 7 
individual antipsychotic agents, including 2 treatment groups by long-acting injection antipsychotic. 
 
EEG recording 
 
The EEG recordings were performed according to the recommendations of the American 
Society for Electroencephalography, with a standard placement of 10 electrodes on 20 electrodes27 on 
an EB-Neuro Galiléo system (Fiorenza, Italy) using 26 cup electrodes located according to the 
international 10–20 system: Fp1/p2, F7/8, F3/4, Fz, FC3/4, FCz, C3/4, T3/4, Cz, CP3/4, CPz, P3/4, 
T5/6, Pz, O1/2, and Oz. The reference electrode was positioned on the nose, and the ground was on an 
Fpz electrode. Electrode impedance was maintained below 5 kΩ. Data were digitalized continuously 
at 1024 Hz, with a 12-bit resolution. A low pass filter was set at 100 Hz prior to the digitalization. 
The EEG was recorded during the waking state, 3 minutes of hyperventilation and intermittent 
photic stimulation for all patients. EEGs were recorded in the morning between 9 am and 12 pm, after 
breakfast. EEGs were recorded for at least 20 min. During the recording, the participant was monitored 
visually and by EEG for signs of drowsiness or sleep, which if happen, lead the technician 
neurophysiologist to speak and arouse him briefly and report this on the medical report. Two 
experienced and certified neurophysiologists interpreted all EEGs independently and one blind 
evaluator blinded to medication, dosage and diagnosis of patients. In case of disagreement, the records 
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were re-evaluated and discussed to reach consensus.  
We assumed that these modifications could be distinguished into 2 categories of severity score: 
« slowing » and « neuronal excitability ». This classification is inspired by the classification of  
Micoulaud-Franchi et al.28 about EEG effects of psychotropic drugs, itself adapted from this of 
Centorrino et al21. This adaptation was done in order to classify the effects of psychotropic drugs in a 
wider range to include iatrogenic encephalopathies and to better guide the clinician about the 
therapeutic strategy. EEG modifications are classified as follows (Table 1). Concerning EEG activity 
slowing: 1 = no slowdown (predominant alpha rhythm), 2 = predominant theta rhythm, 3 = 
predominant theta rhythm with delta bursts, 4 = predominant delta rhythm. Concerning neuronal 
excitability:  A = no signs of neuronal abnormal excitability, B = paroxysmal activities (sharp slow 
waves) occurring only during EEG activation (hyperventilation and/or intermittent photic simulation), 
C = spontaneous paroxysmal activities during the whole recording, D = paroxysmal epileptiform 
discharges. An EEG without anomalies is ranked 1A. One EEG recording suggesting an 
encephalopathy is ranked 4C or 4D. We did not report drowsiness during any EEG recordings. 
Examples of these EEG modifications are presented Figure 1A and Figure 1B. 
 
Statistical methods  
 
 Chi-square and Fisher’s exact test (when appropriate) were used for comparisons of excitability 
score. Comparisons of the mean daily dose of oral antipsychotics according to the molecules with the 
EEG modifications (presence or not, score = C or not) were tested by Student-t test after verification 
if the data displayed a normal distribution. Means are indicated as averages and standard deviations 
(SD, standard deviation). The clinical factors were organized by categories to allow the use of 
contingency tables (chi-square) to test associations with EEG modifications (presence or not). Results 
with p ≥ 0.05 were considered statistically insignificant. The ANOVA test was used to compare the 
equivalent dose of chlorpromazine, the excitability and the type of drug. The analyzes were carried 
out on the data analysis program R (R Development Core Team. R: A language and environment for 
statistical computing R Foundation for Statistical Computing, Vienna, Austria). 
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RESULTS 
 
Eighty-four patients treated with atypical antipsychotics in strict monotherapy were included 
in this retrospective study. Patients received clozapine (n=22), aripiprazole (n=22), olanzapine (n=17), 
risperidone (n=9), quetiapine (n=8), risperidone long-acting injection (n=4), and paliperidone long-
acting injection (n=2) (Figure 2). Among the subjects selected, 19.05% (n=16) were from full-time 
hospitalization and 80.95% (n=68) from day-hospitalization. Their mean age was 34.24 years (SD: 
12.09, range 18 to 74) and 70.24% (n=59) were men. Psychiatric diagnoses (based on the DSM-IV 
criteria) included schizophrenia (69.05% [n=58]), schizoaffective disorder (11.9% [n=10]), bipolar 
disorder (11,9% [n=10]), major depressive episode (2.38% [n=2]) and a non-diagnostic category 
(4.76% [n=4]).  
EEG modifications (score ≠ 1A) were observed in 60,71% of the patients enrolled in the study 
(n=51) (Table 2).  
 
Excitability and slowing score 
 
Epileptiform modifications (score B and C) were associated with clozapine in 20 patients 
(90,9% of the patients of the clozapine group), with olanzapine in 10 patients (58,8% of the olanzapine 
group), with aripiprazole in 11 patients (50%), with quetiapine in 3 patients (37,5%) and with 
risperidone in 4 patients (44,4%), for oral molecules. Slight EEG slowing modifications (score = 2) 
were found in 1 patient with olanzapine (5,88% of the olanzapine group), in 4 patients with clozapine 
(18,2%), and severe (score = 3) for only 1 patient with clozapine (4,55%). No patients with 
encephalopathy (scores 4C or 4D) have been found.  
Unlike typical epileptic abnormalities, the sharp slow waves and other epileptiform activities 
display a particular pattern different from the sharp slow waves observed in vascular insufficiency, for 
example: their locations vary during the recording, they can appear anywhere in cortex, they are 
frequently asynchronous. They do not indicate a focus and they create the impression of “blinking 
cortex”20.  
We found no correlation between the presence or severity of EEG modifications and clinical 
outcomes collected by consulting medical records. The following factors were not associated with 
EEG modifications: duration of disease > 5 years (χ2 = 0.0051, df = 1, p = 0.94), age > 40 years (χ2 = 
0.094, df = 1, p = 0.76), diagnosis of schizophrenia (χ2 = 1.21, df =1, p = 0.27). 
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Type of molecule  
 
The distribution of excitability score according to molecules is clearly different. Clozapine 
induces many excitability modifications (score C is predominant) since paliperidone long-acting 
injection does not modify EEG. The occurrence of epileptiform activities was significantly higher for 
the group of patients receiving clozapine compared to that receiving aripiprazole (χ2 = 9.35, df = 1, p 
= 0.007), olanzapine (p = 0.026, Fisher’s exact test), quetiapine (p = 0.007, Fisher’s exact test), 
risperidone (p = 0.012, Fisher’s exact test). No difference concerning the presence of epileptiform 
activities between other groups of molecules was found. Only clozapine and olanzapine induce EEG 
slowing in 6 patients.  
 
 
Daily dose of antipsychotic  
 
Since the dates of antipsychotic injections were not known, we chose not to include them in 
the dose comparisons in order to avoid « end-of-dose » effects. The results of comparing the mean 
daily doses of oral antipsychotics according to the presence of EEG or absence of EEG modifications 
and according to the presence of a C score or not are presented in Table 3. 
No significant differences were found for the mean daily doses (in mg per day) of antipsychotic 
drugs between patients without EEG modifications and those with EEG modifications (aripiprazole: t 
= 0.34, df = 20, p = 0.73; olanzapine: t = 0.29, df = 15, p = 0.77; clozapine: t = -0.49, df = 20, p = 0.66; 
risperidone: t = 0.45, df = 7, p = 0.67; quetiapine: t = 2.23, df = 6, p = 0.067) (Table 3). 
The mean daily dose of antipsychotics was not different according to molecule between 
patients with severe excitability score (score = C) or not (score = A, B) for aripiprazole (t = -1.74, df 
= 20, p = 0.09) for olanzapine (t = 0.53, df = 15, p = 0.59), for clozapine (t = -1.16, df = 20, p = 0.25), 
for risperidone (t = 0.54, df = 7, p = 0.60) and for quetiapine (t = 1.35, df = 6, p = 0.22) (Table 4). 
 
Chlorpromazine equivalent doses of antipsychotic  
 
The daily doses of oral antipsychotics in chlorpromazine equivalents were different between 
clozapine and aripiprazole (t = 7.018, df = 42, p <0.001), clozapine and olanzapine (t = -5.95, df = 37, 
p <0.001), clozapine and risperidone (t = -5.75, df = 29, p <0.001). Daily doses of chlorpromazine 
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equivalents were different between patients with severe modifications (score = C) versus patients 
without severe modifications (score = A, B) (t = -2.80, df = 76, p = 0.006) (Table 5). No relationship 
was found between excitability score, type of drugs and dose (chlorpromazine equivalent) (F = 1,29, 
p = 0,26) (Figure 3). Nevertheless, score C was more frequently observed with high doses of 
chlorpromazine equivalent (> 500 mg/d).  
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DISCUSSION: 
 
Excitability and slowing score 
 
 In this study, EEG data were examined from 84 patients treated with strict monotherapy of 
clozapine, olanzapine, quetiapine, aripiprazole, risperidone, long-acting risperidone and long-acting 
paliperidone. The modifications related to neuronal excitability (sharp slow waves and/or epileptiform 
activities) and induced by these different molecules are more frequent than in some other studies21,22. 
Precisely, the modifications related to neuronal excitability in this study consist of slow angular 
activities, sometimes slow spikes, whose characteristic is to be of variable and transient localization. 
Unlike typical epileptic abnormalities, these iatrogenic modifications display an asynchronous pattern 
giving an impression of “blinking” cortex. This first result might be explained by the absence of 
benzodiazepines associated with antipsychotic treatment. It has been assumed that co-treatment with 
benzodiazepines may decrease the presence of EEG anomalies induced by antipsychotics21,23. Compared 
to the study conducted by Centorrino et al.21, we found a relationship between the equivalent dose of 
chlorpromazine and EEG modifications (Table 3) probably for the same reason. Nevertheless, we can 
hypothesize that clozapine is probably responsible for this dose effect as shown in Figure 3, since 
clozapine treatments display the higher doses of equivalent dose of chlorpromazine. 
  
An EEG slowing was observed in 6 patients (7.14%) only. In psychiatric patients, diffuse 
slowing accounts for 40% of all electroencephalographic modifications and is therefore the most 
frequent modification detected in EEG29. The diffuse slowing of the EEG activity is often attributed to 
the effects of psychotropic medications30 and compared to the effect of electroconvulsive therapy18, but 
can also be considered as the presence of an encephalopathic process31. Dasberg and Robinson have 
suggested that a diffuse or paroxysmal EEG slowdown under antipsychotic therapy might be indicative 
of better clinical response5. On the contrary, Boutros found a longer duration of hospitalization and an 
increased number of drugs and dosages in the patient group exhibiting an EEG slowdown. He 
suggested that this slowdown could be a reflection of the increased disease severity32. In our study, the 
use of monotherapies might explain the low number of patients with EEG slowing (n=6).  
 
We have proposed a more detailed classification concerning the iatrogenic induced EEG 
modifications. In the present study, the EEG slowing is infrequent. This part of our classification of 
anomalies would be more relevant in the study of association of psychotopic drugs on more severe 
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pathologies and longer duration of evolution. In addition, we have observed that our classification is 
also more adapted to the encephalopathies and their outcome. 
 
Type of molecule  
 
It is known that the risk of convulsive seizures induced by antipsychotics is higher for clozapine 
than for risperidone and aripiprazole33. EEG monitoring is suggested when the daily dose is 20 mg for 
olanzapine34 and 400 mg for clozapine24. Itil and Soldatos advise to repeat a neurophysiological 
examination and to review the history of the disease in search of seizure symptoms if epileptiform 
abnormalities on the EEG with a first-generation antipsychotic treatment were found14. As clozapine, 
olanzapine may induce EEG modifications such as slow waves, sharp waves and paroxysmal slow-
wave discharges22,23,34, but its convulsive risk is considered to be low23. Our results on olanzapine effects 
are consistent with these studies. Only one previous study was interested in the prevalence of EEG 
modifications associated with aripiprazole35. The prevalence was 5,9% and the modifications were not 
severe. We found severe EEG modifications in 27% of our subjects with aripiprazole but our 
classification is different. This result is to be compared with the higher risk of convulsive seizures 
induced by clozapine than risperidone and aripiprazole33. EEG modifications induced by quetiapine are 
uncommon13,21,25 but we found EEG modifications associated with low daily doses of quetiapine. We 
have found no EEG modifications in relation to the daily doses of clozapine as compared to other 
studies36–38. These modifications have been described in relation to the plasma doses of clozapine39–41. We 
were unable to compare plasma clozapine levels due to lack of data. Taking these results altogether it 
is difficult to predict the risk of convulsive seizures using EEG, more so if we postulate that excitability 
modifications are related to the therapeutic effect. 
 
Although the number of patients was low, we found EEG modifications with patients treated 
with risperidone long acting injection. We did not find any studies on the prevalence of EEG changes 
and atypical antipsychotics long-acting injection. Studies on samples of larger subjects would be useful 
for studying the presence of EEG modifications on this type of treatment and more broadly on long-
action atypical antipsychotics. 
 
 EEG modifications and clinical response 
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 Only a few studies have focused on the link between EEG changes and clinical improvement. 
These studies focused on clozapine. Authors reported that EEG modifications under clozapine 
treatment appeared to be associated with good clinical response15–17. In clozapine monotherapy, the 
presence of paroxysmal EEG activities is known to be correlated with clinical efficacy, particularly in 
depressive symptoms15. This observation refers to “forced normalization” in epileptic patients, i.e. the 
emergence of psychotic symptoms when the reduction of paroxysmal activities by anti-convulsant 
therapy occurs in epileptic patients42. On the contrary, epileptic modifications seem to protect against 
psychosis. The induced paroxysmal activities could therefore be considered as the therapeutic effect 
and not only as a side effect. According to this hypothesis, it is possible that the therapeutic effect of 
clozapine and other antipsychotics is related to increase the excitability in subcortical or cortical zones 
of the brain43. Some authors suggested a “reversal normalization” effect, with a possible phenomenon 
of “psychobiological compensation”20. In agreement with this hypothesis, it has been reported that the 
addition of anticonvulsant may reduce the effect of clozapine44,45, although Varma et al. suggest the use 
of prophylactic valproate when the clozapine plasma level exceeds 500 µg/l if the EEG shows clear 
epileptiform discharges24.  
Our study shows that other second-generation antipsychotics (including long-acting injectable 
molecules) also induce EEG modifications. Prospective studies are needed to define the clinical 
significance of types and levels of EEG modifications induced by atypical antipsychotic. These EEG 
modifications require exploring their link with the prognosis and clinical response to second-
generation antipsychotic therapy.  
   
Limitations and conclusion 
 
The limitations of this study are the following: a) this is a retrospective design using the analysis 
of EEG coming from a database and medical records. So, in such a design, all the variables cannot be 
systematically documented; b) a control group of healthy subjects could not be established; c) we were 
unable to correct the equivalence of chlorpromazine by patient weights due to missing data in the 
clinical records; d) the clinical significance of EEG modifications was not specified; e) it was not 
possible to have control groups (healthy subjects, patients with psychiatric disease without treatment) 
because of the study design; f) for the same reason, it was not possible to know of EEG status of the 
patients prior to treatment, g) the number of subjects receiving certain antipsychotics was very low. 
Consequently, prospective studies are needed to define the clinical significance of certain types and 
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levels of EEG modifications. In spite of these limitations, the strength of the study is the analysis of 
strict antipsychotic monotherapies on the brain electric activity. 
In conclusion, this preliminary study has yielded several interesting results. Clozapine in 
monotherapy is the molecule that gives the most frequent EEG modifications compared to other 
atypical antipsychotic. These modifications are rather of the epileptiform type, although an EEG 
slowing is also observed. Quetiapine appears to induce modifications in low doses. Serious 
epileptiform modifications are associated with greater equivalent doses of chlorpromazine. Our results 
reinforce the routine use of electroencephalogram in the monitoring of second-generation 
antipsychotic treatments and support further work to investigate the relationship between EEG 
modifications and clinical symptoms. 
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TABLE 1: Classification for EEG slowing and excitability (inspired by the classification of Micoulaud-Franchi et al.28) 
SLOWING AND EXCITABILITY CLASSIFICATION 
SLOWING SCORE EXCITABILITY SCORE 
RANK DESCRIPTION RANK DESCRIPTION 
1 Absent          (predominant alpha) A Absent           
2 Theta slowing B 
Sporadic epileptiform 
discharges or sharp slow 
waves during 
hyperventilation or photic 
stimulation 
3 Theta slowing with delta bursts C 
Sporadic epileptiform 
discharges or  sharp slow 
waves during the whole 
recording 
4 Delta slowing D Long lasting epilepiform discharges 
	 21	
` 
 
 
      AGE   CHLORPROMAZINE 
EQUIVALENT DOSE 
(mg/d) 
  EEG 
MODIFICATIONS 
  
     SCORE ≠ 1A  
ANTIPSYCHOTICS n   MEAN SD   MEAN SD   n %   
 Immediate, oral            
     ARIPIPRAZOLE 22  28.8 7.77  186.4 100.1  11 50  
     CLOZAPINE 22  39.36 13.25  668.2 344.2  20 90.9  
     OLANZAPINE 17  33 11.81  230.3 144.5  10  58.8  
     QUETIAPINE 8  34.13 9.88  425 319  3 37.5  
     RISPERIDONE 9  33.33 15.16  150 70.7  4  44.4  
Long-acting, injection (LI)            
     RISPERIDONE LI 4  37.5 16.42  137.5 37.9  3  75  
     PALIPERIDONE LI 2   45.5 9.19   175 37.4   0 0   
 
TABLE 2: Percentage of EEG modifications (score >1A) according to the antipsychotic treatment in 84 hospitalized psychiatric patients (n = number of 
patients) 
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  EEG MODIFICATIONS ABSENCE OF EEG MODIFICATIONS   
ANTIPSYCHOTIC n DOSE MEAN (mg/d) SD n DOSE MEAN (mg/d) SD  t-test  
ARIPIPRAZOLE 11 14.55 7.23 11 13.41 8.08 n.s. 
OLANZAPINE 10 11.08 7.30 7 12.14 7.69 n.s. 
CLOZAPINE 20 347.5 172.04 2 200 141.42 n.s. 
RISPERIDONE 4 2.75 1.79 5 3.2 0.96 n.s. 
QUETIAPINE 3 116.67 76.38 5 480 268.33 n.s. 
 
(n: number of patients; n.s . not significant; *Differences statistically significant.) 
 
TABLE 3: Comparison of mean daily doses of each oral antipsychotic according to modifications (score >1A) vs no modifications of EEG.  
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  SCORE=C SCORE=A or B   
ANTIPSYCHOTIC n DOSE MEAN (mg/d) SD n DOSE MEAN (mg/d) SD t-test  
ARIPIPRAZOLE 6 18.33 6.83 16 12.34 7.27 n.s. 
OLANZAPINE 6 10.21 6.73 11 12.23 7.73 n.s. 
CLOZAPINE 18 344 179,3 4 275 158,1 n.s. 
RISPERIDONE 2 2.5 0.71 7 3.14 1.57 n.s. 
QUETIAPINE 2 125 106.07 6 416.66 285.77 n.s . 
 
(n: number of patients; n.s . not significant; *Differences statistically significant.) 
 
TABLE 4: Comparison of mean daily doses of oral antipsychotics according to excitability score.  
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  SCORE=C SCORE =A or B   
ANTIPSYCHOTIC n 
CHLORPROMAZINE 
EQUIVALENT DOSE 
MEAN (mg/d) 
SD n 
CHLORPROMAZINE 
EQUIVALENT DOSE 
MEAN (mg/d) 
SD t-test  
All oral 
antipsychotics 34 463.97 360.11 44 271.7 244.5 p= 0.0064* 
 
(n: number of patients; n.s . not significant; *Differences statistically significant.) 
 
TABLE 5: Comparison of mean daily doses of oral antipsychotics equivalent chlorpromazine according to excitability score. When all the doses are 
converted in chlorpromazine equivalent, one can observe that the EEG excitability increase in patients with high doses of Chlorpormazine EQ.  
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FIGURE 1A: EEG records showing the typical modifications observed in the EEG, for a patient treated by aripiprazole (score 1B). 
 
 
 
FIGURE 1B: EEG records showing the typical modifications observed in the EEG, for a patient treated by clozapine (score 3C) 
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FIGURE 2: Flowchart of the study. 
 
 
5217	Medical	reports	
86	Patients	treated	with	antipsychotic	
monotherapy	
84	subjects	selected:	
ARIPIPRAZOLE,	n=22	
OLANZAPINE,	n=17	
CLOZAPINE,	n=22	
RISPERIDONE,	n=9	
QUETIAPINE,	n=8	
PALIPERIDONE	LONG-ACTING	INJECTION,	n=2	
RISPERIDONE	LONG-ACTING	INJECTION,	n=4	
2	patients	excluded:	
1	for	traumatic	brain	injury	without	complete	
recovery	
1	for	a	previous	drug	overdose	leading	to	coma		
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FIGURE 3:  EEG Results of Excitability score by type and dose (in chlorpromazine equivalent, in mg/day) of each antipsychotic for 78 patients with oral atypical 
antipsychotic monotherapy. 
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